MEDCL.PA - MedinCell S.A.

Paris - Paris Delayed Price. Currency in EUR
7.50
+0.20 (+2.74%)
At close: 5:35PM CEST
Stock chart is not supported by your current browser
Previous Close7.30
Open7.32
Bid0.00 x 0
Ask0.00 x 0
Day's Range7.32 - 7.50
52 Week Range5.45 - 7.55
Volume1,769
Avg. Volume1,938
Market Cap150.546M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.14
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.40
  • Business Wire

    MedinCell Receives a New Grant to Develop a Best-in-class Long-acting Injectable Product for HIV PrEP

    MedinCell receives a grant from The Bill & Melinda Gates Foundation for a product aimed at preventing HIV infection. Pre-exposure prophylaxis (PrEP) strategy has proven efficacy in preventing HIV infection via daily oral administration of antiretroviral drugs. A combination of an investigational PrEP single-agent with MedinCell's long-acting injectable technology could guarantee several months of prevention after a single subcutaneous injection.

  • Business Wire

    MedinCell Partners to Address the Untapped Financial Potential in Animal Health   

    MedinCell (MEDCL.PA) partners with Cornerstone Animal Health to develop a range of best-in-class long-acting injectable veterinary products using MedinCell’s BEPO® proprietary technology. Cornerstone Animal Health is a US-based Animal Health commercialization group formed by seasoned industry veterans, most of them former executives of iconic companies such as Pfizer Animal Health (Zoetis), Merck Animal Health or Merial. The Cornerstone team has an extensive network, deep experience from regulatory development to successful commercialization of innovative products in Animal Health as well as channel management to get products launched.

  • Business Wire

    Long-acting Injectable Antipsychotic Using Medincell’s Technology Receives FDA IND Clearance to Initiate Clinical Activities

    A second long-acting injectable antipsychotic using MedinCell's technology has received FDA IND* clearance to initiate clinical activities. “We have achieved our goal of having at least one clinical trial authorization per year”, stated Christophe Douat, CEO of MedinCell.

  • Do Insiders Own Lots Of Shares In MedinCell S.A. (EPA:MEDCL)?
    Simply Wall St.

    Do Insiders Own Lots Of Shares In MedinCell S.A. (EPA:MEDCL)?

    A look at the shareholders of MedinCell S.A. (EPA:MEDCL) can tell us which group is most powerful. Institutions often...

  • Do Directors Own MedinCell S.A. (EPA:MEDCL) Shares?
    Simply Wall St.

    Do Directors Own MedinCell S.A. (EPA:MEDCL) Shares?

    If you want to know who really controls MedinCell S.A. (EPA:MEDCL), then you'll have to look at the makeup of its share registry. Institutions will often hold stock in bigger Read More...